Does BREXPIPRAZOLE Cause Therapy cessation? 270 Reports in FDA Database
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
According to the FDA Adverse Event Reporting System (FAERS), 270 reports of Therapy cessation have been filed in association with BREXPIPRAZOLE (Rexulti). This represents 2.0% of all adverse event reports for BREXPIPRAZOLE.
270
Reports of Therapy cessation with BREXPIPRAZOLE
2.0%
of all BREXPIPRAZOLE reports
10
Deaths
21
Hospitalizations
How Dangerous Is Therapy cessation From BREXPIPRAZOLE?
Of the 270 reports, 10 (3.7%) resulted in death, 21 (7.8%) required hospitalization, and 3 (1.1%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BREXPIPRAZOLE. However, 270 reports have been filed with the FAERS database.
What Other Side Effects Does BREXPIPRAZOLE Cause?
Weight increased (1,589)
Product use in unapproved indication (1,188)
Off label use (937)
Akathisia (807)
Drug ineffective (730)
Tardive dyskinesia (558)
Tremor (552)
Anxiety (475)
Product use issue (434)
Suicidal ideation (427)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which BREXPIPRAZOLE Alternatives Have Lower Therapy cessation Risk?
BREXPIPRAZOLE vs BREXUCABTAGENE AUTOLEUCEL
BREXPIPRAZOLE vs BRIGATINIB
BREXPIPRAZOLE vs BRILINTA
BREXPIPRAZOLE vs BRILIQUE
BREXPIPRAZOLE vs BRIMONIDINE